Engineered hiPSC-derived vascular graft brings hope for thrombosis-free vascular therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39753109.
- Also identified by DOI 10.1016/j.stem.2024.12.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tissue-engineered vascular conduits (TEVCs) are a promising blood vessel replacement. In a recent publication in Cell Stem Cell,<sup>1</sup> Park et al. developed TEVCs comprised of decellularized human umbilical arteries lined with shear-trained, human induced pluripotent stem cell (hiPSC)-derived endothelial cells (ECs) that resisted thrombosis and exhibited patency upon grafting into the rat inferior vena cava (IVC).
Medical subject headings
- Induced Pluripotent Stem Cells
- Blood Vessel Prosthesis
- Tissue Engineering
- Thrombosis